Join the 'Xofigo' group to help and get support from people like you.
Posted 8 Sep 2014 by Drugs.com
MONDAY, Sept. 8, 2014 – Men newly diagnosed with prostate cancer often turn first to testosterone-depleting therapies, since male hormones help prostate tumors grow. But, those therapies almost always fail over time as the tumor develops resistance, according to oncologists. Now, experts are issuing updated guidelines to help patients in this situation decide what to do next. The guidelines, issued jointly by the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO) in Canada, highlight recent advances in treating this more advanced form of prostate cancer. "We have seen unprecedented progress against advanced prostate cancer recently, with six new treatments approved in the last couple of years," Dr. Ethan Basch, co-chair of the ASCO/CCO panel of experts that developed the guidelines, said in a news release from the two groups. "There are a lot of nuances about ... Read more
Related support groups: Prostate Cancer, Ketoconazole, Zytiga, Nizoral, Casodex, Taxotere, Xtandi, Bicalutamide, Provenge, Docetaxel, Abiraterone, Xofigo, Flutamide, Nilutamide, Cabazitaxel, Jevtana, Sipuleucel-t, Radium 223 Dichloride, Eulexin, Nilandron
Posted 19 Jul 2013 by Drugs.com
WEDNESDAY, July 17 – A newly approved drug that emits radioactive particles can help extend the lives of certain men with advanced prostate cancer, a clinical trial finds. Experts said the results, published in the July 18 issue of the New England Journal of Medicine, offer some good news for men whose cancer has migrated to the bones – a common and painful feature of advanced prostate cancer. The drug, which is marketed as Xofigo, is intended for men with cancer that has spread to the bones despite standard treatment to cut the body's levels of testosterone – the "male" hormone that fuels prostate cancer growth. Known generically as radium-223, the drug emits radioactive particles that zero in on cancerous tissue in the bones. In the new study, researchers found that men given Xofigo had a lower death rate and better quality of life than those on standard treatment only. Xofigo is ... Read more